Revity (RVTY) Q2 2025: China Diagnostics Down High Teens, But Software Orders Hit Record High
Revity’s Q2 2025 revealed a sharp divergence: robust software momentum and pharma stability offset by a surprise China diagnostics pullback, forcing a guidance trim. Management’s nimble cost actions and aggressive buybacks signal confidence in the core portfolio, but regulatory headwinds in China diagnostics now shape near-term expectations. Investors should focus on software durability, cost discipline, and evolving China risk as strategic levers for the next year.
Summary
- China Diagnostics Shock: Unexpected reimbursement policy changes drove a steep decline in China immunodiagnostics volumes.
- Software Franchise Momentum: Signals software delivered record orders and 30%+ organic growth, underscoring portfolio diversification.
- Margin Reset Signals Cost Discipline: Structural cost actions and buybacks support margin recovery despite near-term diagnostic headwinds.
Business Overview
Revity operates as a diversified life sciences and diagnostics company, generating revenue across two major segments: Life Sciences (including reagents, instruments, and the Signals software franchise) and Diagnostics (immunodiagnostics and reproductive health). The company serves pharma, biotech, academic, government, and hospital customers globally, with a meaningful presence in the Americas, Europe, and Asia. Revenue streams span product sales, recurring software subscriptions, and diagnostic test volumes.
Performance Analysis
Q2 2025 results showed resilience in the face of new regulatory and macro headwinds. Organic revenue grew 3%, led by 4% organic growth in life sciences and 2% in diagnostics. The standout was the Signals software franchise, which delivered over 30% organic growth and set a new quarterly orders record, helping drive mid-single-digit growth with pharma and biotech customers. This momentum in software and reagents provided ballast against continued weakness in academic and government end markets, where sales declined low single digits.
Diagnostics performance was hampered by a sudden policy shift in China. The expansion of Diagnosis Related Groups (DRG) reimbursement changes sharply reduced multiplex panel volumes, causing China immunodiagnostics revenue—about 6% of the company total—to fall in the low teens. Management responded with immediate cost actions and further structural changes, but the China headwind drove a 1% reduction in full-year organic growth and EPS guidance. Despite this, robust cash flow conversion (90% year-to-date) and a stepped-up share repurchase program (reducing share count by nearly 6% year-over-year) provided support to per-share results.
- Software Orders Surge: Signals software achieved its largest-ever quarter for orders, with 32% organic growth and 115% net retention.
- China Diagnostics Volume Collapse: DRG policy drove high-teen declines in China immunodiagnostics, now expected to be less than 5% of revenue by 2026.
- Cash Flow and Buybacks: Free cash flow conversion remained robust, supporting nearly $450 million in repurchases year-to-date.
While life sciences and software outperformed, China diagnostics and FX headwinds pressured margins. The company’s operating margin fell 210 basis points YoY but tracked ahead of expectations excluding FX. Management’s swift cost actions and disciplined capital deployment helped offset much of the impact, positioning Revity for margin recovery as structural actions take hold in 2026.
Executive Commentary
"Despite these persistent and in some cases new challenges, Revity continues to perform at a high level. This strong performance exemplifies our unique businesses, which provided us with the proper balance to continue to generate results that were in line to above our expectations."
Prahlad Singh, President and Chief Executive Officer
"Our updated outlook for this business in China is driving the entirety of the change in our overall outlook for the company. Incorporating the impact of these new pressures, we are now looking for organic growth this year for the total company to be in the range of two to 4%, which is slightly below our previous expectations."
Max Grykowiak, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. Software and Digital Expansion
Signals, Revity’s SaaS-based scientific data platform, is emerging as a core growth engine, with more than one-third of its business now SaaS and strong metrics in ARR (annual recurring revenue), APV (average per-vehicle), and retention. This positions Revity to benefit from secular digitalization trends in R&D and life sciences workflows.
2. China Diagnostics Risk Management
The DRG-driven de-bundling policy in China hit high-margin multiplex diagnostics volumes hard, causing immediate revenue and margin drag. Management is actively engaging with key opinion leaders and hospitals to influence policy and expects a gradual shift toward higher-priced single-plex tests, but visibility remains low. Revity is rightsizing its China footprint and reducing discretionary spending to offset the impact.
3. Portfolio Diversification and Resiliency
Life sciences reagents have now grown for five consecutive quarters, and reproductive health (notably newborn screening) is performing well despite global birth rate headwinds. This demonstrates the company’s ability to balance cyclical and secular growth drivers across its portfolio.
4. Cost Structure Flexibility
Revity is accelerating structural cost actions, including global manufacturing footprint reviews and targeted sales and marketing adjustments, particularly in China. These measures are expected to set a 28% operating margin baseline for 2026, above historical levels, and drive enhanced margin expansion as growth normalizes.
5. Capital Allocation Discipline
The company is aggressively returning capital via buybacks, with nearly $450 million repurchased year-to-date and a 6% reduction in share count since last year. M&A remains on the table, but management has not identified targets that meet its financial and strategic criteria, reflecting a disciplined approach amid elevated market valuations.
Key Considerations
Revity’s Q2 underscores the importance of portfolio balance, cost agility, and capital allocation discipline as the company navigates external shocks and internal transformation.
Key Considerations:
- Software Sustainability: Signals’ record orders and SaaS mix provide a recurring revenue base, but investors should watch for order normalization or competitive encroachment.
- China Diagnostics Uncertainty: DRG policy impact is likely to persist through 2025, with potential for further regulatory shifts or volume erosion.
- Margin Reset and Recovery: Structural cost actions are expected to support a 28% margin baseline in 2026, but FX and volume mix remain short-term headwinds.
- Capital Deployment Optionality: With strong cash flow and a healthy balance sheet, Revity retains flexibility for opportunistic M&A or further buybacks.
Risks
China regulatory volatility remains the central risk, with DRG-driven volume declines likely to persist and further reimbursement or policy actions possible. Academic and government funding remains weak, with no near-term recovery in sight. Tariff and FX fluctuations add incremental unpredictability, particularly as Revity evaluates manufacturing realignment and faces evolving global trade conditions. Execution risk exists around cost actions and sustaining software momentum, especially if broader market conditions deteriorate.
Forward Outlook
For Q3 2025, Revity guided to:
- Organic revenue growth of 0% to 2% (total revenue $690 million to $705 million)
- Adjusted operating margin of approximately 26%
- Adjusted EPS in the $1.12 to $1.14 range
For full-year 2025, management lowered guidance:
- Organic growth of 2% to 4% (down 1% from prior outlook)
- Adjusted EPS of $4.85 to $4.95 (down 1% from previous guidance)
Management highlighted:
- China immunodiagnostics expected to be down high teens for the year, now less than 6% of total revenue
- Structural cost actions and operational discipline to support margin recovery and future expansion
Takeaways
Revity’s Q2 demonstrated the company’s ability to offset external shocks with internal strengths, but the China diagnostics reset is a material drag that will shape near-term results.
- Software and Life Sciences Provide Growth Anchors: Signals software and reagents growth continue to drive performance, even as diagnostics faces turbulence.
- Cost and Capital Actions Cushion Margin Pressure: Accelerated cost measures and buybacks protect EPS and set the stage for margin expansion in 2026.
- China Remains the Key Swing Factor: Investors should monitor regulatory developments and the pace of single-plex test adoption as the main wildcards for Revity’s recovery trajectory.
Conclusion
Revity’s Q2 2025 was defined by a dual narrative: software and core life sciences outperformance balanced against a sharp diagnostics setback in China. Margin reset and disciplined capital deployment position the company for recovery, but China risk and market caution demand ongoing vigilance.
Industry Read-Through
Revity’s results highlight the vulnerability of diagnostics players to sudden policy shifts in China, echoing similar pressures across global diagnostics and medtech peers. Software-driven growth and SaaS adoption are increasingly critical for portfolio resilience, with recurring revenue and high retention metrics serving as key differentiators. Cost agility and capital return discipline are becoming industry table stakes as macro and regulatory headwinds persist. Life sciences suppliers with diversified end markets and digital expansion are best positioned to weather sector volatility, while those reliant on China or academic/government funding must brace for ongoing disruption.